A Phase 2 interventional study of Intra-arterial infusion of chemotherapy in Retinoblastoma and Eye Cancer, sponsored by Stanford University. Withdrawn at 1 site in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2012-05-14.
Sponsored by Stanford University · Phase 2, Interventional, and Treatment
Phase II study of selective intra-arterial infusion of chemotherapy for intraocular retinoblastoma
124 studies on the registry are indexed under Retinoblastoma; 23 are open to participants now.
Browse Retinoblastoma studies →Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.
Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Response: Globe salvage rate (Eyes saved/Eyes treated). This will be determined by clinical ocular examination.
Time frame: Follow-up will be performed for one year from treatment date.
This study is withdrawn, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stanford University